cbdMD, Inc. Stock

YCBD

US12482W4087

Pharmaceuticals

Market Closed - NYSE 16:10:00 2026-09-10 EDT			5-day change	1st Jan Change
0.4780 ^USD	-2.83%		-0.62%	-64.59%

09-02	CbdMD, Inc. entered into a definitive asset purchase agreement to acquire Operating assets and brands of Twinlab Consolidation Corporation for $2.9 million.	CI
08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT

Last Transcript : cbdMD, Inc.

CbdMD, Inc., Q3 2026 Earnings Call, Aug 13, 2026

08-13

More transcripts

Analysts' recommendations : cbdMD, Inc.

08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT
23-10-05	Maxim Starts Coverage on cbdMD with Buy Rating, $3 Price Target	MT
21-06-18	CbdMD : Cantor Fitzgerald Adjusts Price Target for cbdMD to $3.25 from $4.10, Maintains Neutral Rating	MT

More recommendations

Managers and Directors : cbdMD, Inc.

Manager	Title	Age	Since
T. Kennedy CEO	Chief Executive Officer	47	2023-02-28
Zeb Booker CTO	Chief Tech/Sci/R&D Officer	-	2018-12-31
Sibyl Swift CTO	Chief Tech/Sci/R&D Officer	45	-

Director	Title	Age	Since
Bakari Sellers BRD	Director/Board Member	41	2017-02-28
William Raines BRD	Director/Board Member	66	2019-04-18
Scott Stephen CHM	Chairman	60	2022-06-02

More insiders

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-09-10	US$0.4780	-2.83%	71,617
26-09-09	US$0.4919	-1.56%	71,766
26-09-08	US$0.4997	+5.07%	34,356
26-09-04	US$0.4756	-1.12%	83,692
26-09-03	US$0.4810	-3.76%	358,746

Delayed Quote NYSE

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.4780

Average target price

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Cap	5.36M 4.61M 4.35M 3.96M 7.4M 512M 7.47M 51.76M 19.92M 260M 20.11M 19.67M 825M	P/E 2026 *	-1.45x	P/E 2027 *	-2.52x
Enterprise Value	5.36M 4.61M 4.35M 3.96M 7.4M 512M 7.47M 51.76M 19.92M 260M 20.11M 19.67M 825M	EV / Sales 2026 *	0.24x	EV / Sales 2027 *	0.19x
Free-Float	90%	Yield 2026 *	-	Yield 2027 *	-

09-02	CbdMD, Inc. entered into a definitive asset purchase agreement to acquire Operating assets and brands of Twinlab Consolidation Corporation for $2.9 million.	CI
08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT
08-13	CbdMD, Inc., Q3 2026 Earnings Call, Aug 13, 2026
08-13	CbdMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026	CI
07-14	CbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina	CI
07-14	CbdMD Expands Oasis Beverage Distribution to South Carolina	MT
07-07	Cbdmd Completes Self-Affirmed Gras Determination for Broad Spectrum Cbd	CI
07-01	CbdMD Launches Oasis Mixer, A Hemp-Derived Zero-Proof THC Spirit	CI
06-16	CbdMD, Inc. Appoints Wade Brown as Chief Marketing Officer	CI
05-14	CbdMD, Inc., Q2 2026 Earnings Call, May 14, 2026
05-14	CbdMD reports 19% year-over-year and 12% sequential revenue growth	RE
05-14	CbdMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
04-06	Hawkeye Systems, Inc. Announces President and Directorate Appointments	CI

09-02	CbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women's Beauty, Weight Loss and Longevity Wellness	PR
08-13	CbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026	PR
08-10	CbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter Results	PR
08-03	CbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products	PR
07-27	CbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access	AQ

1 day	-2.83%
1 week	-0.62%
Current month	-2.45%
1 month	-15.55%
3 months	-30.92%
6 months	-28.68%
Current year	-64.59%

1 week	0.47	0.5
1 month	0.45	0.62
Current year	0.45	1.34
1 year	0.45	2.56
3 years	0.45	13.84
5 years	0.45	820.8
10 years	0.45	2,606.4

cbdMD, Inc. Stock

Stocks

YCBD

US12482W4087

Pharmaceuticals

Valuation : cbdMD, Inc.

Chart: cbdMD, Inc.

Latest news : cbdMD, Inc.

Last Transcript : cbdMD, Inc.

Analysts' recommendations : cbdMD, Inc.

Press Releases : cbdMD, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : cbdMD, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/14/26	Jeffrey Porter	Free	Director	1,572	0.0150%
4/14/26	William Raines	Free	Director	1,572	0.0150%
4/14/26	Bakari Sellers	Free	Director	1,572	0.0150%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CBDMD, INC.	-2.83%	-0.62%	-29.92%	-95.37%	5.51M
ELI LILLY AND COMPANY	-0.11%	-3.16%	+48.82%	+91.49%	1,002B
JOHNSON & JOHNSON	-0.27%	-4.34%	+51.52%	+65.89%	644B
ABBVIE INC.	+1.63%	-2.00%	+20.49%	+71.12%	443B
ROCHE HOLDING AG	-0.63%	-3.09%	+29.84%	+34.59%	343B
NOVARTIS AG	+0.43%	-14.61%	+11.32%	+27.26%	262B
ASTRAZENECA PLC	+0.93%	-3.19%	-1.31%	+8.41%	245B
AMGEN INC.	-2.25%	-13.88%	+37.33%	+47.43%	212B
NOVO NORDISK A/S	-0.90%	-5.06%	-18.47%	-57.75%	199B
GILEAD SCIENCES, INC.	-0.58%	-4.24%	+25.65%	+90.54%	181B
Average	-0.39%	-4.82%	+17.53%	+28.36%	352.97B
Weighted average by Cap.	+0.07%	-4.39%	+31.98%	+57.11%

	2026 *	2027 *
Net sales	21.92M 18.85M 17.79M 16.21M 30.29M 2.1B 30.57M 212M 81.54M 1.06B 82.33M 80.53M 3.38B	28.6M 24.59M 23.2M 21.14M 39.51M 2.73B 39.87M 276M 106M 1.39B 107M 105M 4.4B
Net income	-3.33M -2.87M -2.7M -2.46M -4.6M -319M -4.65M -32.2M -12.39M -162M -12.51M -12.24M -513M	-4.95M -4.25M -4.01M -3.66M -6.83M -473M -6.9M -47.8M -18.4M -240M -18.57M -18.17M -762M
Net Debt	-	-

Markets		Quality
NYSE	YCBD	Delayed
CBOE	YCBD	Real-time